Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q3 FY26 results · Oct–Dec 2025
Panacea Biotec reported revenue from operations of ₹165.19 crore (up 1.0% from Q3 FY25) and net profit of ₹3.89 crore (down 12.4% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 165.19 | 163.49 | +1.0% | 141.13 | +17.0% |
| Other income | 2.28 | 3.62 | −37.0% | 6.40 | −64.4% |
| Total income | 167.47 | 167.11 | +0.2% | 147.53 | +13.5% |
| Profit before tax | 6.49 | 4.38 | +48.2% | (19.17) | Turned profit |
| Net profit for the period | 3.89 | 4.44 | −12.4% | (14.01) | Turned profit |
| Attributable to shareholders of the company | 3.98 | 4.52 | −11.9% | (13.92) | Turned profit |
| EPS, basic (₹) | 0.65 | 0.74 | −12.2% | (2.27) | Turned profit |
| Net margin (%) | 2.4 | 2.7 | -9.9 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 99.31 | 108.43 | −8.4% | 90.81 | +9.4% |
| Other income | 3.84 | 3.32 | +15.7% | 3.61 | +6.4% |
| Total income | 103.15 | 111.75 | −7.7% | 94.42 | +9.2% |
| Profit before tax | (9.47) | 9.65 | Turned loss | (20.93) | Loss narrowed |
| Net profit for the period | (7.36) | 9.65 | Turned loss | (15.64) | Loss narrowed |
| EPS, basic (₹) | (1.20) | 1.58 | Turned loss | (2.55) | Loss narrowed |
| Net margin (%) | -7.4 | 8.9 | -17.2 |
Consolidated
- Filed with BSE
- 11 Feb 2026, 19:55 IST
- Board meeting
- 11 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 11 Feb 2026, 19:55 IST
- Board meeting
- 11 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE